These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 28002618)

  • 1. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
    Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
    Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting YAP in malignant pleural mesothelioma.
    Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
    J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.
    Li H; Huang Z; Gao M; Huang N; Luo Z; Shen H; Wang X; Wang T; Hu J; Feng W
    J Exp Clin Cancer Res; 2016 Sep; 35(1):134. PubMed ID: 27599610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin inhibits growth of human glioma in vitro without light activation.
    Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice.
    Hao F; Xu Q; Wang J; Yu S; Chang HH; Sinnett-Smith J; Eibl G; Rozengurt E
    PLoS One; 2019; 14(5):e0216603. PubMed ID: 31100067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
    Li T; Guo T; Liu H; Jiang H; Wang Y
    Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
    Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
    Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE‑cadherin/EphA2/MMP9/MMP2 expression.
    Guo JQ; Zheng QH; Chen H; Chen L; Xu JB; Chen MY; Lu D; Wang ZH; Tong HF; Lin S
    Int J Oncol; 2014 Sep; 45(3):1065-72. PubMed ID: 24938458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1.
    Zhang H; Ramakrishnan SK; Triner D; Centofanti B; Maitra D; Győrffy B; Sebolt-Leopold JS; Dame MK; Varani J; Brenner DE; Fearon ER; Omary MB; Shah YM
    Sci Signal; 2015 Oct; 8(397):ra98. PubMed ID: 26443705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
    Alhothali M; Mathew M; Iyer G; Lawrence HR; Yang S; Chellappan S; Padmanabhan J
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP activation is an early event and a potential therapeutic target in liver cancer development.
    Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
    J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
    J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of YAP Inhibition on Human Leukemia HL-60 Cells.
    Chen M; Wang J; Yao SF; Zhao Y; Liu L; Li LW; Xu T; Gan LG; Xiao CL; Shan ZL; Zhong L; Liu BZ
    Int J Med Sci; 2017; 14(9):902-910. PubMed ID: 28824329
    [No Abstract]   [Full Text] [Related]  

  • 17. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
    Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
    Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. lncRNA
    Li N; Yang G; Luo L; Ling L; Wang X; Shi L; Lan J; Jia X; Zhang Q; Long Z; Liu J; Hu W; He Z; Liu H; Liu W; Zheng G
    Clin Cancer Res; 2020 Apr; 26(7):1736-1748. PubMed ID: 31831555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
    Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
    J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.
    Xia Y; Zhang YL; Yu C; Chang T; Fan HY
    PLoS One; 2014; 9(11):e109575. PubMed ID: 25369529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.